PAINREFORM Stock Soars 90% on NVIDIA Connect Entry and LayerBio Pact

Introduction

PAINREFORM LTD (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company headquartered in Tel Aviv, Israel. The firm focuses on reformulating established therapeutics to provide extended post-surgical pain relief while reducing reliance on opioids. As of August 19, 2025, PRFX shares traded at $2.5502, reflecting a 90.31% increase, with a trading volume of 7,089,721 shares.

Corporate Structure

Founded in 2007, PAINREFORM operates with a compact team of 2–10 employees. Its management includes:

• Ehud Geller, Ph.D., Executive Chairman & Interim CEO, who served as Executive Vice President at Teva Group and president of Interpharm Laboratories.
• Prof. Eli Hazum, CTO, with previous roles in leadership at Glaxo’s Research Triangle Park and as a general partner at Medica VC.
• Dr. Sigal Aviel, COO, previously Chief R&D Officer at MediWound and Vice President of clinical and regulatory affairs at Biokine.
• Mrs. Rita Keynan, Vice President of Pharmaceutical Operations, bringing over 25 years of experience managing CMC activities and regulatory filings at Foamix and VYNE Therapeutics.

Pain management by Morgan Rovang

Recent Developments and News

August 19, 2025: In SEC Form 6-K, PAINREFORM announced its acceptance into the NVIDIA Connect Program, which indicates a potential collaboration in technology solutions for drug development and data analytics.

August 13, 2025: A Form 6-K filing detailed a strategic investment in LayerBio, aimed at entering the $9 billion global cataract surgery market. The investment seeks to advance a non-opiate, non-steroidal postoperative NSAID delivery system under FDA-approved protocols.

July 10, 2025: PAINREFORM entered a Preferred Stock Purchase Agreement with LayerBio. The company committed $600,000 (net of a prior $50,000 bridge loan) plus up to $2.4 million in milestone-based payments tied to LayerBio’s Phase II clinical trial of OcuRing-K.

Financial and Strategic Analysis

PAINREFORM’s SEC filings do not provide complete financial statements, but public data indicate:

• Market Capitalization: approximately $2.7 million (2.01 million shares outstanding)
• EPS (TTM): –32.16; P/E (TTM): –0.04; Fwd P/E (NTM): –0.05
• EBITDA (TTM): $14.657 million; ROE (TTM): 321.92%

The company utilizes the FDA’s 505(b)(2) pathway to facilitate the reformulation of existing drugs, which can reduce development timelines and costs. Its partnership with LayerBio allows for diversification of its product pipeline into ophthalmology, while membership in the NVIDIA Connect Program may enhance its data-driven research and development capabilities.

Market Position and Industry Context

PAINREFORM’s lead candidate, PRF-110, is a viscous, oil-based solution intended for localized, extended analgesia without the need for repeated dosing. This product is differentiated from current non-opiate topical alternatives that often utilize liposomes or synthetic polymers containing bupivacaine. By focusing on established molecules and proprietary delivery systems, PAINREFORM operates in a specialized area that merges drug reformulation with targeted pain management—markets known for their regulatory complexities and demand for safer, longer-acting therapeutics.

tl;dr

• PAINREFORM shares increased by 90.31% to $2.5502 on August 19, 2025 (volume of 7.09 million).
• The company joined the NVIDIA Connect Program on August 19, indicating potential for enhanced technological integration in its operations.
• An August 13 filing disclosed a strategic investment in LayerBio to develop an ophthalmic NSAID delivery system for the $9 billion cataract surgery market.
• An agreement on July 10 outlines a financial commitment of up to $3 million for LayerBio’s Phase II trial of OcuRing-K.
• Upcoming catalysts include data from LayerBio’s clinical trial milestones and potential collaborations through NVIDIA.